In brief: Cytopia; LCT; Rockeby
Thursday, 10 March, 2005
Cytopia (ASX:CYT) today filed an Investigational New Drug Application with the US Food and Drug Administration, seeking approval to test its cancer drug candidate CYT997 in the clinic.
Rockeby biomed (ASX:RBY) has announced the resignation of Dr John Warmington as the company's director of research and development. Warmington assume a consultancy role with the company as chief scientist. Dr David Capes will take up the position of vice president of research and development.
Xenotransplantation company Living Cell Technologies (ASX: LCT) has appointed Paris Brooke as general manager. Brooke was formerly policy and communication manager at AusBiotech.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
